Pressure-suit combined with pelvic stop-flow: a feasibility study in a bovine model

Eur J Surg Oncol. 2007 Feb;33(1):114-8. doi: 10.1016/j.ejso.2006.09.034. Epub 2006 Nov 7.

Abstract

Background: Isolated pelvic perfusion exposes tissue to high drug doses and may benefit patients with advanced malignancy. However, leakage is a limit to this technique.

Aims: The aim of the study is to increase the perfusion ratio between local and systemic compartments on isolated pelvic perfusion. We hypothesised that an inflated pressure-suit placed above the level of aortic and caval stop flow could decrease leakage from the regional to the systemic blood compartment in a bovine model.

Method: As the size of the pressure-suit was adapted for use in humans, we performed our experimental study on 6 calves which are big enough to fit into the suit. We used an inflated pressure-suit placed at low (40mmHg) and high pressures (125mmHg) above the level of aortic and caval stop-flow. A pharmacokinetic study with cisplatinum was performed in both compartments.

Results: After injection of the drug, the mean ratio of drug concentration in the locoregional/systemic compartment was 43.1. After 30min, this mean ratio was 4 and 9.7 for a pressure-suit pressure of 40mmHg and 125mmHg, respectively. At pressure-suit pressures of 40mmHg and 125mmHg, pelvic perfusion achieved pelvic/systemic exposure ratios of 5.9 and 14.9 at 30min, respectively. Leakage at 30min was higher when the pressure-suit was inflated at low pressure (40mmHg, mean 18%). When the pressure-suit was inflated at high pressure, leakage was lower (125mmHg, mean 7%).

Conclusions: The pressure-suit increased the perfusion ratio between pelvic and systemic compartments in a bovine model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacokinetics
  • Cattle
  • Chemotherapy, Cancer, Regional Perfusion / instrumentation*
  • Cisplatin / administration & dosage*
  • Cisplatin / pharmacokinetics
  • Disease Models, Animal
  • Equipment Design
  • Feasibility Studies
  • Gravity Suits*
  • Neoplasms, Experimental / drug therapy*
  • Neoplasms, Experimental / metabolism
  • Pelvic Neoplasms / drug therapy*
  • Pelvic Neoplasms / metabolism
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Cisplatin